Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-01-04
1998-11-03
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 3, 530303, A61K 3828, C07K 1462
Patent
active
058308539
ABSTRACT:
A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.
REFERENCES:
patent: 3014844 (1961-12-01), Thiel
patent: 4524769 (1985-06-01), Wetterlin
patent: 4534345 (1985-08-01), Wetterlin
patent: 4548922 (1985-10-01), Carey et al.
patent: 4613500 (1986-09-01), Suzuki et al.
patent: 4668218 (1987-05-01), Virtanen
patent: 4690952 (1987-09-01), Kagatani et al.
patent: 4746508 (1988-05-01), Carey et al.
patent: 4788221 (1988-11-01), Kagatani et al.
patent: 4847298 (1989-07-01), Alexander et al.
patent: 4895719 (1990-01-01), Radhakrishnan
patent: 4900730 (1990-02-01), Miyauchi
patent: 4907583 (1990-03-01), Wetterlin et al.
patent: 4959358 (1990-09-01), Carey et al.
patent: 4963367 (1990-10-01), Ecanow
patent: 4994439 (1991-02-01), Longenecker et al.
patent: 5006343 (1991-04-01), Benson et al.
patent: 5011678 (1991-04-01), Wang
patent: 5118494 (1992-06-01), Schultz
patent: 5122127 (1992-06-01), Stanley
patent: 5122376 (1992-06-01), Aliverti
patent: 5179079 (1993-01-01), Hansen et al.
patent: 5192548 (1993-03-01), Velasquez et al.
patent: 5200393 (1993-04-01), Weiner
patent: 5202129 (1993-04-01), Samejima et al.
patent: 5254330 (1993-10-01), Ganderton et al.
patent: 5260306 (1993-11-01), Boardman et al.
patent: 5284656 (1994-02-01), Platz et al.
patent: 5288498 (1994-02-01), Stanley et al.
patent: 5341800 (1994-08-01), Clark et al.
patent: 5348730 (1994-09-01), Greenleaf
patent: 5354562 (1994-10-01), Platz et al.
patent: 5364838 (1994-11-01), Rubsamen
patent: 5376386 (1994-12-01), Ganderton et al.
patent: 5384133 (1995-01-01), Boyes et al.
patent: 5419315 (1995-05-01), Rubsamen
patent: 5437271 (1995-08-01), Hodson et al.
patent: 5482032 (1996-01-01), Smith et al.
patent: 5482706 (1996-01-01), Igari et al.
patent: 5506203 (1996-04-01), Backstrom et al.
patent: 5514670 (1996-05-01), Friedman
patent: 5518998 (1996-05-01), Backstrom et al.
Allenby et al., The Absorption of Insulin Across the Respiratory Tract of the Guinea-Pig (U), The Aerosol Society, Fourth Annual Conference 1990, pp. 129-134.
Aungst and Rogers, Comparison of the Effects of Various Transmucosal Absorption Promoters on Buccal Insulin Delivery, Int. J. Pharm. (Netherlands), 1989, 53/3, 227-235.
Bjork, Starch Microspheres as a Nasal Delivery System for Drugs, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 103, 1993.
Bjork and Edman, Degradable Starch Microspheres as a Nasal Delivery System for Insulin, Int. J. Pharm. 47:233-238, 1988.
Brange et al., Monomeric Insulins and Their Experimental and Clinical Implications, Diabetes Care 13:923-954, 1990.
Edman and Bjork, Routes of Delivery: Case Studies, Advanced Drug Delivery Reviews 8:165-177, 1992.
Igawa et al., Effect of Absorption Promoters in Intranasal Administration of Human Fibroblast Interferon as a Powder Dosage Form in Rabbits, Chem. Pharm. Bull. 37:418-421, 1989.
Lasker, The Diabetes Control and Complications Trial, N. Engl. J. Med. 329:1035-1036, 1993.
Mishima et al., Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Inuslin in Rats, J. Pharm -Dyn. 10:624-631, 1987.
Morita et al., Effects of Various Absorption Promoters on Pulmonary Absorption of Drugs with Different Molecular Weights, Biol. Pharm. Bull. 16:269:262, 1993.
Nagai et al., Powder Dosage Form of Insulin for Nasal Administration, J. Controlled Release 1:15-22, 1984.
"Diabetes Mellitus", Ch. VI in Scientific American Medicine, Scientific American, Inc., Apr. 1993.
The Diabetes Control and Complications Trial Research Group, The Effect of Intensive Treatment of Diabetes on the Development . . . Complications in Insulin-Dependent Diabetes Mellitus, N. Engl. J. Med. 329:977-86, 1993.
Pontiroli et al., Nasal Administration of Glucagon and Human Calcitonin to Healthy Subjects: a Comparison of Powders and Spray Solutions and of Different Enhancing Agents, Eur. J. Clin. Pharmacol. 37:427-430, 1989.
Schipper et al., Nasal Insulin Delivery with Dimethyl-.beta.-Cyclodextrin as an Absorption Enhancer in Rabbits: Powder More Effective than Liquid Formulations, Pharmaceutical Research 10:682-686, 1993.
Selam and Charles, Devices for Insulin Administration, Diabetes Care 13:955-979, 1990.
Touitou and Rubenstein, Targeted Enteral Delivery of Insulin to Rats, Int. J. Pharm. (Amst.), 30(2-3), 1986, 95-100.
Wigley et al., Insultin Across Respiratory Mucosae by Aerosol Delivery, Diabetes 20:552-556, 1971.
Zinman, Medical Intelligence -- The Physiologic Replacement of Insulin, N. Engl. J. Med. 321:363-370, 1989.
Olanoff et al., "Method to Enhance Intranasal Peptide Delivery," in Controlled-Release Technology Pharmaceutical Applications, Lee et al., American Chemical Societ, 301-309, 1987.
Ruin, Sydsvenska (Dagbladet), Monday, Jun. 12, 1989, Diabetics May Not Need Their Insulin Shots.
Almer et al., Diabetes Res. and Clin. Pract. 5:S163 (1988).
Bjork, Acta Univ. Uppsala, Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 103 (1993).
Timsina et al., Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers, Int. J. Pharmaceutics 101:1-13 (1994).
Komada et al., Intratracheal Delivery of Peptide and Protein Agents: Absorption from Solution and Dry Powder by Rat Lung, J. Pharm. Sci. 83:863-867 (1994).
Lee et al., Intranasal Bioavailability of Insulin Powder Formulations: Effect of Permeation Enhancer-to-Protein Ration, J. Pharm Sci. 80:725-729 (1991).
Schipper et al., Nasal Insulin Delivery with Dimethyl-.beta.-Cyclodextrin as an Absorption Enhancer in Rabbits: Powder More Effective than Liquid Formulations, Pharm. Res. 10:682-686 (1993).
Lee et al., Mucosal Penetration Enhancers for Facilitation of Peptide and Protein Drug Absorption, Critical Rev. Therapeut. Drug Carrier Systems 8:91-192 (1991).
Wearley, Recent Progress in Protein and Peptide Delivery by Noninvasive Routes, Critical Rev. Therapeut. Drug Carrier Systems 8:331-394 (1991).
Laube et al., Preliminary Study of the Efficacy of Insulin Aerosol Delivered by Oral Inhalation in Diabetic Patients, JAMA 269:2106-2109 (1993).
Dahlback, Regional Administration to Drugs to the Rabbit Respiratory Tract, Effects on Absorption, J. Aerosol. Medicine 1:222-223 (1988).
Yoshida et al., Absorption of Insulin Delivered to Rabbit Trachea Using Aerosol Dosage Form, J. Pharma. Sci. 68:670-671 (1979).
Damasy et al., Diabetes Res. and Clin. Pract. 5:S163 (1988).
Chandler et al., Nasal Absorption in Rats. II. Effect of Enhancers on Insulin Absorption and Nasal Histology, Int. J. Pharmaceutics 76:61-70 (1991).
Hirai et al., Effect of Surfactants on the Nasal Absorption of Insulin in Rat, Int. J. Pharmaceutics 9:165-172 (1981).
Gordon et al., Nasal Absorption of Insulin: Enhancement by Hydrophobic Bile Salts, Proc. Natl. Acad. Sci. USA 82:7419-7423 (1985).
Moses et al., Insulin Administered Intranasally as an Insulin-Bile Salt Aerosol, Diabetes 32:1040-47 (1983).
Wigley, et al., Insulin Across Respiratory Mucosae by Aerosol Delivery, Diabetes 20:552-556 (1971).
Cutie et al., The Role of Dispersing Agents in Inhalation and Intransal Aerosol Suspensions, Aerosol. Age 30:52-54 (1985).
Backstrom Kjell Goran Erik
Dahlback Carl Magnus Olof
Edman Peter
Johansson Ann Charlotte Birgit
Astra Aktiebolag
Gupta Anish
Tsang Cecilia J.
LandOfFree
Systemic administration of a therapeutic preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systemic administration of a therapeutic preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systemic administration of a therapeutic preparation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-689114